Every year AACE seeks out world-renowned experts in the field of endocrinology, and the 27th Annual AACE Scientific & Clinical Congress in Boston, Massachusetts will not disappoint.
This year’s lineup of scholarly faculty showcases the best of the best in endocrinology. Learners will have the opportunity to earn CME as presenters discuss the latest treatments, guidelines, devices and other therapies available to help your patients. There’s no better opportunity to enhance your knowledge than through the various sessions held throughout the AACE Annual Meeting.
In addition, you will have the chance to ask a question or two from the speaker on the spot, using an interactive app created especially for the Annual Meeting.
FEATURED SPEAKER | C. Ronald Kahn, MDAmong the distinguished list of those whose contributions have fundamentally altered the understanding and treatment of diabetes – Dr. Paul Langerhans, Sir Frederick Banting, Dr. Elliott Joslin, Dr. Priscilla White – is that of Dr. C. Ronald Kahn.
As Joslin Diabetes Center’s Research Director from 1981 to 2000, he revolutionized the field as the first investigator to decode insulin signal transduction and the mechanisms of altered signaling in disease.
Under his leadership, his laboratory discovered the insulin receptor kinase, its two primary substrates and the molecular components of the insulin-signaling network, work that has been essential to understanding the pathogenesis of type 2 diabetes. More recent discoveries in Dr. Kahn’s laboratory have reshaped understanding of obesity by showing that adipocytes have different developmental origins and cellular functions that lead to risk of metabolic disease.
And during his seven-year tenure as Joslin’s President, Joslin’s research programs grew more than 20-fold, while clinical and educational activity tripled.
Currently Joslin’s Chief Academic Officer and Head of the Section of Integrative Physiology and Metabolism, Dr. Kahn has authored more than 800 original publications and is among the most highly cited scientists in the diabetes field worldwide. He is the recipient of more than 70 awards and honors, including the Harold Hamm International Prize for Biomedical Research, known as the Nobel prize for diabetes research.
Beverly M.K. Biller, MD, FACPBeverly MK Biller, MD is Professor of Medicine at Harvard Medical School and a faculty member of the Neuroendocrine Unit at Massachusetts General Hospital (MGH), Boston, Massachusetts.
Dr. Biller directs the Clinical Fellowship in Endocrinology and Metabolism at MGH. She also directs the annual Harvard Medical School & MGH Continuing Medical Education course "Clinical Endocrinology" that welcomes endocrinologists to Boston every March. She currently serves on the AACE Task Force to Update the Growth Hormone Guidelines, and is on the Endocrine Society Council.
Major research interests include the pathogenesis, diagnosis and treatment of Cushing’s disease, acromegaly, prolactinomas, and growth hormone deficiency (GHD) in adults. Dr. Biller has co-authored Clinical Guidelines regarding adult GHD and Cushing’s disease for the AACE and The Endocrine Society, respectively.
Anthony N. Hollenberg, MDLong before translational research gained momentum as a “bench-to-bedside” approach to the development of new diagnostics and therapies from biomedical discoveries, Dr. Anthony Hollenberg was ahead of the curve.
His interest in the field was sparked more than 30 years ago when, as a Harvard College undergraduate, he attempted to clone gonadotropin genes as part of his senior thesis. Today, he is renowned for pioneering research that has advanced understanding regarding how the thyroid gland develops from embryonic stem cells and the regulatory mechanisms of thyroid function. His discoveries represent an important step toward the goal of better treating thyroid diseases and being able to permanently rescue thyroid function.
Equal parts scientist, physician and educator, Dr. Hollenberg serves as Chief of the Thyroid Unit and Endocrinology, Diabetes and Metabolism Division at Beth Israel Deaconess Medical Center (BIDMC), Associate Professor of Medicine at Harvard Medical School and is training a new generation of physician-researchers as Co-Director of the Clinical Investigator Training Program at BIDMC and Harvard Medical School, one of a few such specialized training programs nationwide.
Andrew F. Stewart, MDThe leading authority on the replication and regeneration of insulin-producing human pancreatic beta cells, Dr. Andrew Stewart has devoted more than 30 years to endocrinology and diabetes patient care and basic and clinical scientific research.
He and his research team at the University of Pittsburgh School of Medicine were the first to demonstrate that growth factors could drive beta cell replication in vivo in mammals and improve glucose control in living animals.
Today, as Scientific Director of the Mount Sinai Health System’s Diabetes, Obesity and Metabolism Institute (DOMI) – the research counterpart to Mount Sinai’s nationally recognized Diabetes Center – he leads a team of scientists whose work focuses on understanding the basic mechanisms involved in metabolic diseases in order to develop prevention and treatment programs for those conditions.
Dr. Stewart is also the Irene and Dr. Arthur M. Fishberg Professor of Medicine (Endocrinology, Diabetes and Bone Disease) at the Icahn School of Medicine at Mount Sinai and the recipient of the Gerald D. Aurbach Award for Outstanding Translational Research.
Sundeep Khosla, MDWhen it comes to understanding skeletal physiology and disease, including the key role of estrogen in regulating bone metabolism in men, and the causal role of cellular senescence in mediating age-related bone loss, Mayo Clinic’s Dr. Sundeep Khosla is considered the leading expert.
Dr. Khosla is a longtime NIH-funded principal investigator/researcher on skeletal health, including studies on the physiology of bone metabolism in the aging population. His research group in the Osteoporosis and Bone Biology Laboratory at Mayo Clinic in Rochester is examining how fundamental aging mechanisms in bone lead to increased skeletal fragility. In addition, Dr. Khosla is researching the adverse effects of type 2 diabetes on bone structure and material properties.
He has served as a Consultant in the Division of Endocrinology, Diabetes, Metabolism and Nutrition at and Professor of Medicine at the Mayo Clinic College of Medicine in Rochester since 1991. Also, he holds a joint appointment as Consultant in the Department of Physiology and Biomedical Engineering at Mayo Clinic.
Ashok Balasubramanyam, MDDr. Ashok Balasubramanyam is among an elite group of physicians and scientists nationwide who have joined forces to solve rarely seen, often-unrecognized and difficult-to-solve medical cases from around the country.
In his role as co-leader of the Baylor College of Medicine team selected by the National Institute of Health (NIH) to be one of seven clinical sites for the NIH’s Undiagnosed Diseases Network, he is intrinsically involved in developing an understanding of the genetic basis of novel and rare metabolic syndromes and advancing research, especially into disease mechanisms. The network is modeled after an NIH pilot program that enrolled a number of people with intractable medical conditions, and often used genomic approaches such as gene sequencing to provide diagnoses.
A Professor of Medicine in the Diabetes Research Center, Division of Diabetes, Endocrinology and Metabolism at Baylor College of Medicine, Dr. Balasubramanyam’s research interests are varied and have included HIV-associated metabolic disease such as dyslipidemia and insulin resistance. He has also explored syndromes of ketosis-prone diabetes.
He is also Vice President for Academic Integration and Senior Associate Dean for Academic Affairs at Baylor College of Medicine.
Martin Schlumberger, MDDr. Martin Schlumberger is an internationally renowned endocrinologist who has focused his career on endocrine oncology as Professor of Oncology at University Paris-Sud. His contributions are numerous, particularly in his main fields of interests which include the use of radioactive isotopes in medicine and treatment of thyroid tumors.
Since 2009, he has served as director of the Centre Expert National pour les cancers de la thyroïde réfractaires, a network for rare cancers of the French National Cancer Institute. He founded the Endocrine Tumor Group of the EORTC and built links with the corresponding U.S. groups. He organized centers for thyroid tumors in several locations, including Catania, San Giovanni Rotondo, Roma and Minsk. He is “professore a contrato” at University La Sapienza in Roma.
A much-sought-after speaker, Dr. Schlumberger has given more than 200 invited conferences during international meetings, has received several awards in France and has served as an invited professor at Johns Hopkins, Memorial Sloan Kettering Cancer Center, Mayo Clinic, Harvard and other prestigious institutions.